OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy-Nucleic Acids is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Effective intravitreal gene delivery to retinal pigment epithelium with hyaluronic acid nanospheres	222
Novel eRF3a degrader enhances gentamicin-induced premature termination codon readthrough in epidermolysis bullosa	122
Forced enhancer-promoter rewiring to alter gene expression in animal models	116
Antisense oligonucleotide-mediated exon 27 skipping restores dysferlin function in dysferlinopathy patient-derived muscle cells	108
AAV-vectored base editor trans-splicing delivers dystrophin repair	106
LinQURE: A novel AAV gene silencing platform that supports multi-transcript targeting for complex disorders	91
An oversized AAV8 vector to deliver CPS1	89
Insights into the regulatory role of epigenetics in moyamoya disease: Current advances and future prospectives	87
SPRINGing forward: Advancing RNA editing efficiency and precision with engineered ADAR2	86
Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells	84
Retraction Notice to: Hypoxic tumor-derived exosomal circular RNA SETDB1 promotes invasive growth and EMT via the miR-7/Sp1 axis in lung adenocarcinoma	76
Unlocking RNA mysteries: Predicting subcellular localizations with AI	75
A novel gene therapy platform for the treatment of type 2 diabetes and obesity	74
Single-cell transcriptome profiling implicates the psychological stress-induced disruption of spermatogenesis	73
Durable HTT silencing using non-evolved dCas9 epigenome editors in patient-derived cells	72
Base editing strategies for in vivo correction of two highly recurrent phenylketonuria variants	72
Implications of circular transcripts in DM1 pathomechanism	66
A potent GalNAc-siRNA drug, RBD1016, leads to sustained HBsAg reduction and seroconversion in mouse models of HBV infection	65
Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation	64
Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1	61
MicroRNA-466 and microRNA-200 increase endothelial permeability in hyperglycemia by targeting Claudin-5	60
Inefficacy of anti-VEGF therapy reflected in VEGF-mediated photoreceptor degeneration	59
Ferroptosis as a therapeutic target in glioblastoma: Mechanisms and emerging strategies	59
Comparison of MALAT1 antisense oligonucleotide distribution following intracerebroventricular and lumbar intrathecal routes of administration	59
Alleviation of ischemia-reperfusion induced renal injury by chemically modified SOD2 mRNA delivered via lipid nanoparticles	59

Enhanced molecular dynamic simulation studies unravel long-range effects caused by sequence variations and partner binding in RNA aptamers	57
Efficient transfected liposomes co-loaded with pNrf2 and pirfenidone improves safe delivery for enhanced pulmonary fibrosis reversion	56
Implications of miR-148a-3p/p35/PTEN signaling in tau hyperphosphorylation and autoregulatory feedforward of Akt/CREB in Alzheimer’s disease	56
All roads lead to cure: Diversity of oligonucleotides in DM1 therapy	54
MASQ: A multiplex qPCR platform for quantitative alternative splicing analysis in clinical specimens	52
Single-swap editing for the correction of common Duchenne muscular dystrophy mutations	52
Endothelial derived, secreted long non-coding RNAs Gadlor1 and Gadlor2 aggravate cardiac remodeling	52
Comparative immunogenic and structural characterization of virus-like particle and inactivated whole-virion vaccines against enterovirus D68	51
Progress and prospect of minicircle as a minimized non-viral DNA vector in gene therapy and regenerative medicine	51
cncFinder: A graph-attention-network-based interpretable learning model to identify bifunctional long non-coding RNAs	50
Mitochondrial double-stranded RNAs as a pivotal mediator in the pathogenesis of Sjӧgren’s syndrome	50
A bimolecular modification strategy for developing long-lasting bone anabolic aptamer	49
Seeking stability for gene addition in inborn errors of metabolism	49
Modulation of miR-29 influences myocardial compliance likely through coordinated regulation of calcium handling and extracellular matrix	49
Using RNA-targeting CRISPR-Cas13 and engineered U1 systems to target ABCA4 splice variants in Stargardt disease	49
DUX4 reduction and muscle function improvement by subcutaneous delivery of gapmer antisense oligonucleotides	49
Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models	48
Deficiency of miR-409-3p improves myocardial neovascularization and function through modulation of DNAJB9/p38 MAPK signaling	47
Topical application of a CCL22-binding aptamer suppresses contact allergy	47
Right on target: The next class of efficient, safe, and specific RNAi triggers	46
PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration	46
Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD	46